Nasdaq

Teva Pharmaceutical Industries Presents Final Analysis of PEARL Study Demonstrating Sustained Effectiveness of AJOVY in Migraine Prevention at EAN 2025 Congress

Teva Pharmaceutical Industries Ltd. announced the final analysis of the PEARL Phase 4 study at the European Academy of Neurology Congress 2025, confirming that AJOVY (fremanezumab) is effective in ...
The American Journal of Managed Care

Final MIRASOL Trial Analysis Confirms Consistent Efficacy of Mirvetuximab Soravtansine

The final analysis showed similar overall survival, progression-free survival, and objective response rates, with no new safety signals identified compared with the primary analysis. The primary ...
Morningstar

Ivonescimab HARMONi-A Study Final OS Analysis Results Presented at SITC 2025 with OS HR=0.74

HONG KONG, Nov. 7, 2025 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) is excited to announce that the final Overall Survival (OS) analysis results from the HARMONi-A study, a Phase III study evaluating ...
ascopubs.org

Final analysis of a multicenter, open-label, phase 2 study evaluating the efficacy and safety of tislelizumab (TIS) in combination with fruquintinib (F) in patients (pts) with ...

Impact of body mass index on immunotherapy outcomes and complications in solid tumor patients: A real-world evidence analysis. Median progression-free survival, mo (95% CI) 4.6 (3.4, 7.4) 4.6 (3.6, ...